keyword
MENU ▼
Read by QxMD icon Read
search

Hyperuricemia and Chronic kidney disease

keyword
https://www.readbyqxmd.com/read/29124443/identification-of-cdc42bpg-as-a-novel-susceptibility-locus-for-hyperuricemia-in-a-japanese-population
#1
Yoshiki Yasukochi, Jun Sakuma, Ichiro Takeuchi, Kimihiko Kato, Mitsutoshi Oguri, Tetsuo Fujimaki, Hideki Horibe, Yoshiji Yamada
Chronic kidney disease and hyperuricemia are serious global health problems. Recent genome-wide association studies have identified various genetic variants related to these disorders. However, most studies have been conducted in a cross-sectional manner. To identify novel susceptibility loci for chronic kidney disease or hyperuricemia, we performed longitudinal exome-wide association studies (EWASs), using ~ 244,000 genetic variants and clinical data of Japanese individuals who had undergone annual health checkups for several years...
November 9, 2017: Molecular Genetics and Genomics: MGG
https://www.readbyqxmd.com/read/29113336/asymptomatic-hyperuricemia-and-coronary-artery-disease-in-elderly-patients-without-comorbidities
#2
Junnan Wu, Guangtao Lei, Xiao Wang, Yuezhong Tang, Huan Cheng, Guihua Jian, Xianfeng Wu, Niansong Wang
Because many subjects with hyperuricemia have comorbidities, it can be difficult to differentiate the role of hyperuricemia from that of other comorbidities of coronary artery disease (CAD). Subjects aged ≥ 65 years were enrolled in the study and were available at enrollment and at 5-year follow-up. Subjects were excluded if they were overweight or obese, hypertensive, diabetic, hyperlipidemic, had a pre-existing cardiovascular disease, a history of gout or hyperuricemia on medications, or chronic kidney disease as estimated by a glomerular filtration rate (eGFR) < 60 mL/min per 1...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29071435/the-effect-of-xanthine-oxidase-inhibitors-on-blood-pressure-and-renal-function
#3
REVIEW
Marilisa Bove, Arrigo F G Cicero, Claudio Borghi
Several epidemiological studies have demonstrated the existence of a correlation between high serum uric acid (SUA) levels, hypertension, and chronic kidney disease (CKD). Xantine oxidase inhibitors (XOI) are the most powerful uric acid lowering drugs, with presumed beneficial effects on cardiovascular and renal system. The multifactorial mechanism linking hyperuricemia with cardiovascular and renal diseases involves both the SUA level and the xanthine oxidase (XO) activity. In this context, the clinical research has been recently focused at assessing the efficacy of urate-lowering drugs active on XO in patients with abnormal blood pressure values and renal dysfunction...
October 25, 2017: Current Hypertension Reports
https://www.readbyqxmd.com/read/29057261/aprepitant-for-the-treatment-of-chronic-refractory-pruritus
#4
REVIEW
Alice He, Jihad M Alhariri, Ronald J Sweren, Madan M Kwatra, Shawn G Kwatra
Chronic pruritus is a difficult condition to treat and is associated with several comorbidities, including insomnia, depression, and decreased quality of life. Treatment for chronic itch includes corticosteroids, antihistamines, and systemic therapies such as naltrexone, gabapentin, UV light therapy, and immunomodulatory treatments, including azathioprine, methotrexate, and cellcept. However, some patients still remain refractory to conventional therapy. Aprepitant is a neurokinin-1 receptor antagonist approved for the prevention of chemotherapy-induced and postoperative nausea and vomiting (CINV, PONV)...
2017: BioMed Research International
https://www.readbyqxmd.com/read/29032376/impact-of-uric-acid-levels-on-kidney-disease-progression
#5
Hernan Rincon-Choles, Stacey E Jolly, Susana Arrigain, Victoria Konig, Jesse D Schold, Georges Nakhoul, Sankar D Navaneethan, Joseph V Nally, Michael B Rothberg
BACKGROUND: Hyperuricemia is associated with the progression of chronic kidney disease (CKD), but it is not known whether the relationship is causal. We examined the association of hyperuricemia and uric acid lowering therapy (UALT) with progression of CKD in patients with CKD 3 and 4 in the Cleveland Clinic CKD registry. METHODS: We included 1,676 patients with CKD stages 3 and 4 from Ohio, who had measured their uric acid (UA) levels a year prior to the recording of the second eGFR <60 mL/min/1...
2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/29029600/clinical-features-and-ckd-related-quality-of-life-in-patients-with-ckd-g3a-and-ckd-g3b-in-china-results-from-the-chinese-cohort-study-of-chronic-kidney-disease-c-stride
#6
Zhangzhe Peng, Jinwei Wang, Qiongjing Yuan, Xiangcheng Xiao, Hui Xu, Yanyun Xie, Wei Wang, Ling Huang, Yong Zhong, Xiang Ao, Luxia Zhang, Minghui Zhao, Lijian Tao, Qiaoling Zhou
BACKGROUND: This study aimed to compare clinical features and health-related quality of life (HRQoL) in the Chinese chronic kidney disease (CKD) 3 population and determined the necessity of the subdivision of CKD3 in Chinese patients with CKD. METHODS: Participants with stage 3 CKD (18-74 years of age) were recruited at 39 clinical centers located at 28 cities in 22 provinces of China. The sociodemographic status, medical history, anthropometric measurements, and lifestyle behaviors were documented at entry, and blood and urine samples were collected...
October 13, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/29017210/-asymptomatic-hyperuricemia-risk-factors-for-the-development-and-progression-of-chronic-kidney-disease
#7
Anna-Isabelle Kälsch, Bernd Krüger
No abstract text is available yet for this article.
October 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/29017152/high-uric-acid-induced-epithelial-mesenchymal-transition-of-renal-tubular-epithelial-cells-via-the-tlr4-nf-kb-signaling-pathway
#8
Huifang Liu, Jiachuan Xiong, Ting He, Tangli Xiao, Yan Li, Yanlin Yu, Yinghui Huang, Xinli Xu, Yunjian Huang, Jingbo Zhang, Bo Zhang, Jinghong Zhao
BACKGROUND: Hyperuricemia is an independent risk factor for causing chronic kidney disease and contributes to kidney fibrosis. After urate crystals get deposited in the kidney, they can cause hyperuricemia nephropathy, leading to glomerular hypertrophy and renal tubular interstitial fibrosis. Recent data showed that uric acid (UA) could induce epithelial mesenchymal transition (EMT) of renal tubular cells, in which NRLP3 inflammatory pathway was involved. However, whether TLR4/NF-κB signaling pathway is also involved in EMT of renal tubular cells induced by UA is not clear...
2017: American Journal of Nephrology
https://www.readbyqxmd.com/read/28980141/asymptomatic-hyperuricemia-is-it-time-to-intervene
#9
Binoy J Paul, K Anoopkumar, Vinod Krishnan
Whether to treat hyperuricemia uncomplicated by articular gout, urolithiasis, or uric acid nephropathy is an exercise in clinical judgment and universal agreement is lacking. Patients with coronary artery disease, chronic kidney disease, and early onset hypertension with persistent hyperuricemia are likely to be benefited with urate-lowering therapy. The paradigm of the causative association of hyperuricemia with cardiovascular and chronic kidney diseases seems to have progressed from skepticism to increasing evidence of a true relationship...
December 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28952391/the-problem-of-cardio-renal-diseases-in-patients-with-gout
#10
Claudio Ferri
BACKGROUNDS: Although evidence is mounting on the role of hyperuricemia in cardio-renal disease, continuing doubt remains as to whether hyperuricemia can be considered a major causal cardiovascular risk factor. In addition, available data suggest that treatment may be beneficial, even in the absence of overt gout, when hyperuricemia accompanies other clinical conditions, such as urate deposition, advanced chronic kidney disease, or cardiovascular risk factors. METHODS AND RESULTS: Analysis of the literature suggests there would be sufficient evidence warranting clinical trials to determine whether lowering uric acid levels would be clinically beneficial in the prevention or treatment of cardiovascular and renal diseases...
November 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28927237/augmented-association-between-blood-pressure-and-proteinuria-in-hyperuricemic-patients-with-non-nephrotic-chronic-kidney-disease
#11
K Kohagura, M Kochi, T Miyagi, R Zamami, K Nagahama, K Yonemoto, Y Ohya
Background: Hyperuricemia (HU) may enhance susceptibility to hypertensive renal damage via disrupted autoregulation of glomerular hemodynamics. The effect of HU on the association between blood pressure (BP) and proteinuria remains unknown in patients with chronic kidney disease (CKD). Methods: In total, 109 patients with non-nephrotic CKD (55 men and 54 females) who underwent renal biopsy were recruited. Arteriolar hyalinosis was semiquantitatively assessed via arteriole grading...
September 13, 2017: American Journal of Hypertension
https://www.readbyqxmd.com/read/28915657/the-prevalence-subtypes-and-associated-factors-of-hyperuricemia-in-lupus-nephritis-patients-at-chronic-kidney-disease-stages-1-3
#12
Simeng Liu, Yijun Gong, Hong Ren, Wen Zhang, Xiaonong Chen, Tong Zhou, Xiao Li, Nan Chen
There is a high prevalence of hyperuricemia (HUA) in the chronic kidney disease (CKD) population. However, there's a dearth of research on HUA's prevalence, subtypes, early detection, and treatment strategies of HUA in lupus nephritis (LN) patients. The aim of this study is to address these knowledge gaps. LN patients presenting to the Department of Nephrology at Shanghai Rui Jin Hospital from January 2011 to January 2016 were recruited. The effective sample size was derived using the power analysis. The demographic, clinical and laboratory characteristics of the LN patients with HUA were compared with those of patients without HUA...
August 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28904879/renoprotective-effects-of-febuxostat-compared-with-allopurinol-in-patients-with-hyperuricemia-a-systematic-review-and-meta-analysis
#13
Sollip Kim, Hyun-Jung Kim, Hyeong-Sik Ahn, Se Won Oh, Kum Hyun Han, Tae-Hyun Um, Chong-Rae Cho, Sang Youb Han
BACKGROUND: Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However, it is not widely used in patients with CKD because of its serious adverse event. Febuxostat can be alternatively used for patients who are intolerable to allopurinol. We aimed to determine renoprotective effect and urate-lowering effect between the two drugs. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials to assess the effects of febuxostat compared to allopurinol in patients with hyperuricemia...
September 2017: Kidney Research and Clinical Practice
https://www.readbyqxmd.com/read/28846182/effects-of-sodium-glucose-co-transporter-2-sglt2-inhibitors-on-serum-uric-acid-level-a-meta-analysis-of-randomized-controlled-trials
#14
Yumo Zhao, Lubin Xu, Dongli Tian, Peng Xia, Hua Zheng, Li Wang, Limeng Chen
The aim of this study was to describe the effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid (SUA) in patients with type 2 diabetes mellitus (T2DM). PubMed, CENTRAL, EMBASE and ClinicalTrials.gov were searched for randomized controlled trials of SGLT2 inhibitors in patients with T2DM up to May 20, 2017. A total of 62 studies, comprising 34 941 patients, were included. Any of the SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, tofogliflozin, luseogliflozin or ipragliflozin) significantly decreased SUA levels compared with control (total weighted mean difference [WMD] -37...
August 28, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28794291/allopurinol-against-progression-of-chronic-kidney-disease
#15
Sima Golmohammadi, Afshin Almasi, M Manouchehri, Hamid Reza Omrani, Mohammad Reza Zandkarimi
INTRODUCTION: Hyperuricemia is common in approximately 50% of patients with kidney failure due to decreased uric acid excretion, and it has been recently known as an independent factor in the progression of renal insufficiency. Allopurinol inhibits the production of uric acid. The aim of this study was to evaluate the effect of allopurinol on chronic kidney disease progression. MATERIALS AND METHODS: In a clinical trial, patients with stages 3 and 4 of chronic kidney disease were divided into two groups to receive allopurinol, 100 mg, daily and placebo for 12 months...
July 2017: Iranian Journal of Kidney Diseases
https://www.readbyqxmd.com/read/28793050/relationship-between-uric-acid-levels-and-risk-of-chronic-kidney-disease-in-a-retrospective-cohort-of-brazilian-workers
#16
L S N Chini, L I S Assis, J R Lugon
Uric acid (UA) levels are increased in patients with kidney dysfunction. We analyzed the association between asymptomatic hyperuricemia and new-onset chronic kidney disease (CKD). A retrospective cohort study was designed to collect data from employees of an energy generation and distribution company in the city of Rio de Janeiro, Brazil, who had undergone the company's annual medical checkup from 2008 to 2014. People with ≤2 years of follow-up, with baseline estimated glomerular filtration rate (eGFR) <60 mL·min-1·(1...
August 7, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/28759644/the-influence-of-serum-uric-acid-on-renal-function-in-patients-with-calcium-or-uric-acid-stone-a-population-based-analysis
#17
Yoshimi Tanaka, Shingo Hatakeyama, Toshikazu Tanaka, Hayato Yamamoto, Takuma Narita, Itsuto Hamano, Teppei Matsumoto, Osamu Soma, Teppei Okamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Ippei Takahashi, Shigeyuki Nakaji, Yuriko Terayama, Tomihisa Funyu, Chikara Ohyama
OBJECTIVES: To determine the influence of serum uric acid (UA) levels on renal impairment in patients with UA stone. MATERIALS AND METHODS: We retrospectively analyzed 463 patients with calcium oxalate and/or calcium phosphate stones (CaOx/CaP), and 139 patients with UA stones. The subjects were divided into the serum UA-high (UA ≥ 7.0 mg/dL) or the UA-low group (UA < 7.0 mg/dL). The control group comprised 3082 community-dwelling individuals that were pair-matched according to age, sex, body mass index, comorbidities, hemoglobin, serum albumin, and serum UA using propensity score matching...
2017: PloS One
https://www.readbyqxmd.com/read/28752287/effects-of-topiroxostat-in-hyperuricemic-patients-with-chronic-kidney-disease
#18
Taro Horino, Yutaka Hatakeyama, Osamu Ichii, Tatsuki Matsumoto, Yoshiko Shimamura, Kosuke Inoue, Yoshio Terada, Yoshiyasu Okuhara
BACKGROUND: Hyperuricemia is associated with chronic kidney disease (CKD). Although topiroxostat, a novel, non-purine, selective xanthine oxidase inhibitor, has a strong effect against hyperuricemia, limited data are available on its renoprotective effect against CKD. METHODS: This study was conducted between October 2014 and May 2016. Thirty patients (20 male, 10 female) were administered 40 mg/day of topiroxostat twice daily. All patients were followed for a year...
July 27, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/28749169/effects-of-sodium-glucose-cotransporter-2-inhibitors-on-serum-uric-acid-in-type-2-diabetes-mellitus
#19
Hala Ahmadieh, Sami Azar
Hyperuricemia has been linked to metabolic syndrome, cardiovascular disease, and chronic kidney disease. Hyperuricemia and type 2 diabetes mellitus were inter-related, type 2 diabetes mellitus was more at risk of having a higher serum uric acid level, and also individuals with higher serum uric acid had higher risk of developing type 2 diabetes in the future. Insulin resistance seems to play an important role in the causal relationship between metabolic syndrome, type 2 diabetes, and hyperuricemia. Oral diabetic drugs that would have additional beneficial effects on reducing serum uric acid levels are of importance...
September 2017: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/28748122/asymptomatic-hyperuricemia-and-chronic-kidney-disease-narrative-review-of-a-treatment-controversial
#20
REVIEW
Theodoros Eleftheriadis, Spyridon Golphinopoulos, Georgios Pissas, Ioannis Stefanidis
Today there is plausible evidence both on experimental and epidemiological basis, that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (CKD). Nevertheless, the role of serum uric acid lowering treatment in CKD is still a matter of serious controversy. Review of randomised controlled trials, suggests that there may be an improvement of renal function with allopurinol treatment in CKD stage 3-5. However, these studies have included a relatively limited number of participants and provide insufficient information on adverse events and on the incidence of the end stage renal disease...
September 2017: Journal of Advanced Research
keyword
keyword
22053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"